Medication info

Celtidin Tablet 150 mg (Ranitidine Hydrochloride)

Prescription medicationTabletOralExpired
Ingredient · strength
Ranitidine Hydrochloride›168mg / 1 tablet
Manufacturer / importer
Telcon RF Pharmaceutical Co., Ltd.
Appearance
White round film-coated tablet
Packaging
30 tablets/bottle, 300 tablets/bottle
Approval status
Expired

MFDS item code 201403325 · Approved 2014.07.23

This product's status changed to Expired on 2024.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of gastric acid disorders (including ulcers, etc.); improvement of gastric mucosal lesions; prevention of Mendelson syndrome
Who takes it
Adults · Children
Adult dose
Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers: Administer this medicine 150 mg orally twice daily, or 300 mg once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The same dosage applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for prevention of gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. These conditions usually heal within 4 weeks, or within 8 weeks when caused by nonsteroidal anti-inflammatory drugs, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. Gastroesophageal reflux disease: Administer this medicine 150 mg twice daily for 8 weeks, or 300 mg once daily at bedtime. For patients with severe gastroesophageal reflux disease, the dose may be increased to 150 mg 4 times daily. Zollinger-Ellison syndrome: Start treatment with an initial dose of this medicine 150 mg 3 times daily, and increase the dose if necessary. In severe cases, up to 6 g daily may be administered as directed by a physician. For upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, and acute gastric mucosal lesions, treatment is usually initiated with an injection; once oral administration is possible, switch to oral treatment with this medicine 150 mg twice daily. Preanesthetic medication (prevention of Mendelson syndrome): Administer this medicine 150 mg 2 hours before induction of anesthesia. It is preferable to also administer 150 mg on the evening before surgery. For improvement of gastric mucosal lesions (erosion, bleeding, erythema, edema) associated with the following conditions: acute gastritis and acute exacerbation of chronic gastritis: Administer this medicine 150 mg once daily at bedtime. Hyperacidity, heartburn, acid regurgitation: For patients aged 12 years or older, administer this medicine 75 mg orally twice daily (liquid formulation only). In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.
Child dose
Ages 8 〜 18: 150 mg per dose (2 mg/kg body weight) may be administered up to twice daily.

Ingredients

Manufacturer
Telcon RF Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of gastric acid disorders (including ulcers, etc.); improvement of gastric mucosal lesions; prevention of Mendelson syndrome

  • Gastric and duodenal ulcers
  • Zollinger-Ellison syndrome
  • gastroesophageal reflux disease
  • Mendelson syndrome
  • post-operative ulcers
  • gastric and duodenal ulcers due to non-steroidal anti-inflammatory drug administration
  • gastric mucosal lesions
  • erosion
  • bleeding
  • erythema
  • edema
  • acute gastritis
View approved original text

This medication is used in the treatment of gastric and duodenal ulcers, Zollinger-Ellison syndrome, and gastroesophageal reflux disease. It also helps prevent Mendelson syndrome prior to anesthesia and aids in the treatment of post-operative ulcers. It is effective against gastric and duodenal ulcers caused by the use of non-steroidal anti-inflammatory drugs (NSAIDs). It is used to improve gastric mucosal lesions such as acute gastritis or exacerbations of chronic gastritis, and upper gastrointestinal bleeding. Additionally, it is effective in relieving heartburn and acid regurgitation due to excessive gastric acid. Overall, it is used to improve symptoms related to gastric and esophageal diseases.

How to take

Adult dose

Administer ranitidine 150 mg orally twice daily, in the morning and at bedtime. Gastric and duodenal ulcers: Administer this medicine 150 mg orally twice daily, or 300 mg once daily at bedtime. A higher cure rate may be achieved, particularly in patients with duodenal ulcers, by administering 300 mg twice daily, in the morning and at bedtime. The same dosage applies to combination therapy for ulcers caused by nonsteroidal anti-inflammatory drugs or for prevention of gastric and duodenal ulcers during long-term use of nonsteroidal anti-inflammatory drugs. These conditions usually heal within 4 weeks, or within 8 weeks when caused by nonsteroidal anti-inflammatory drugs, although healing may occasionally take longer in some patients. For patients with recurrent ulcers who responded well to short-term treatment with this medicine, administer 150 mg once daily at bedtime as maintenance therapy. Gastroesophageal reflux disease: Administer this medicine 150 mg twice daily for 8 weeks, or 300 mg once daily at bedtime. For patients with severe gastroesophageal reflux disease, the dose may be increased to 150 mg 4 times daily. Zollinger-Ellison syndrome: Start treatment with an initial dose of this medicine 150 mg 3 times daily, and increase the dose if necessary. In severe cases, up to 6 g daily may be administered as directed by a physician. For upper gastrointestinal bleeding due to peptic ulcers, acute stress ulcers, and acute gastric mucosal lesions, treatment is usually initiated with an injection; once oral administration is possible, switch to oral treatment with this medicine 150 mg twice daily. Preanesthetic medication (prevention of Mendelson syndrome): Administer this medicine 150 mg 2 hours before induction of anesthesia. It is preferable to also administer 150 mg on the evening before surgery. For improvement of gastric mucosal lesions (erosion, bleeding, erythema, edema) associated with the following conditions: acute gastritis and acute exacerbation of chronic gastritis: Administer this medicine 150 mg once daily at bedtime. Hyperacidity, heartburn, acid regurgitation: For patients aged 12 years or older, administer this medicine 75 mg orally twice daily (liquid formulation only). In patients with severe renal impairment and creatinine clearance of 50 mL/min or less, administer 150 mg once daily at bedtime. Depending on the patient's condition, the dosing interval may be extended to 12 hours or longer. Hemodialysis reduces the plasma concentration of the medicine; therefore, readjust the dosing schedule immediately after hemodialysis. Adjust the dose as appropriate according to age and symptoms.

Child dose

Ages 8 〜 18: 150 mg per dose (2 mg/kg body weight) may be administered up to twice daily.

Precautions

This medication should not be used in patients who have had allergic reactions to this drug or any of its components. Additionally, it should be avoided in patients with a history of a rare blood disorder known as acute porphyria, as it may worsen symptoms. Patients with impaired renal function may have increased blood concentration due to poor excretion of the drug, and therefore may require a reduced dose or an increased dosing interval. Patients with hepatic impairment also require caution, and those with a history of drug allergies, the elderly, and patients taking non-steroidal anti-inflammatory drugs should use it carefully. In particular, since it may mask symptoms of gastric cancer, it should be used only after confirmation of cancer status in patients with gastric ulcers or in middle-aged individuals with newly appeared dyspeptic symptoms. Patients with gastric and duodenal ulcers infected with Helicobacter pylori should also undergo treatment to eradicate the bacteria. While taking this medication, rare but serious adverse events such as allergic reactions, blood abnormalities, liver dysfunction, cardiac rhythm issues, digestive symptoms, and neurological abnormalities may occur, so any unusual symptoms should be reported to a doctor immediately. During treatment, the patient's condition should be continuously monitored, using only the minimum effective dose. If ineffective, alternative treatments should be considered. The elderly, as well as those with chronic pulmonary illnesses, diabetes, and weakened immune systems, may have a higher risk of pneumonia and should be monitored closely. If dizziness or drowsiness occurs after taking this medication, driving or operating dangerous machinery should be avoided. There may be interactions with other medications, especially if taking anticoagulants or specific drugs, so consultation with a doctor and blood tests to monitor the condition is necessary. When taken with the medication sucralfate, it is recommended to space the doses by two hours to prevent reduced absorption of this drug. Women who are pregnant or may become pregnant, as well as those who are breastfeeding, should carefully weigh the benefits and risks when using this medication. Safety in pediatric populations has not been sufficiently established, thus caution is necessary. The elderly may have decreased renal function, requiring dosage adjustments and extended intervals. When using this medication, some tests may yield false positive results, necessitating adjustments to testing methods. No significant problems have been reported with overdose, but appropriate treatment such as vomiting or gastric lavage may be necessary, and blood dialysis may be used to remove the drug if needed. This medication should be stored out of reach of children, and transferring it to another container is not advisable for quality and safety reasons. Caution is required with long-term use, as decreased gastric acid secretion may lead to bacterial overgrowth in the stomach; animal studies have reported effects on ocular tissues, so ocular examinations may be necessary with long-term use.

Side effects

  • Anaphylactic shock
  • urticaria
  • angioedema
  • rash
  • fever
  • bronchospasm
  • hypotension
  • chest pain
  • granulocytopenia
  • increased serum creatinine levels
Show 56 more
  • leukopenia
  • thrombocytopenia
  • hypoplastic bone marrow syndrome
  • aplastic anemia
  • refractory anemia
  • agranulocytosis
  • pancytopenia
  • acquired immune hemolytic anemia
  • eosinophilia
  • general fatigue
  • weakness
  • subcutaneous and mucosal hemorrhage
  • liver function impairment
  • jaundice
  • hepatitis
  • bradycardia
  • heart block
  • tachycardia
  • vasculitis
  • constipation
  • nausea
  • vomiting
  • abdominal bloating
  • abdominal pain
  • loss of appetite
  • diarrhea
  • acute pancreatitis
  • dizziness
  • drowsiness
  • seizures
  • headache
  • heaviness in the head
  • insomnia
  • agitation
  • anxiety
  • mental confusion
  • depression
  • hallucinations
  • blurred vision
  • involuntary movement disorders
  • altered consciousness
  • gynecomastia
  • galactorrhea
  • erectile dysfunction
  • decreased libido
  • arthralgia
  • myalgia
  • rhabdomyolysis
  • skin rash
  • erythema multiforme
  • alopecia
  • stomatitis
  • pruritus
  • mucous membrane syndrome
  • toxic epidermal necrolysis
  • acute interstitial nephritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to light and should be stored in a container that prevents light exposure. It is advisable to keep it at room temperature between 1°C and 30°C. Proper storage will maintain the drug's effectiveness and safety.

Appearance and packaging

Appearance

White round film-coated tablet

Package unit

30 tablets/bottle, 300 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.